Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR731 Single Agent or in Combination With ARPIs in Metastatic Prostate Cancer
NCT07570979Phase 1Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of INR731 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose-limiting toxicities at 28 days, Incidence and severity of Adverse Events and Serious Adverse Events and 2 more. Started May 2026; status: recruiting.
02
Drugs
INR731
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07570979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570979.